

Journals & Books







Share

Export



Neurochemistry International Volume 79, December 2014, Pages 1-11

## Mechanism of the beneficial effect of melatonin in experimental Parkinson's disease

Fatos Belgin Yildirim <sup>a</sup>, Ozlem Ozsoy <sup>b</sup>, Gamze Tanriover <sup>c</sup>, Yasemin Kaya <sup>a</sup>, Eren Ogut <sup>a</sup>, Burcu Gemici <sup>b</sup>, Sayra Dilmac <sup>c</sup>, Ayse Ozkan <sup>b</sup>, Aysel Agar <sup>b</sup> <sup>△</sup> 

Mutay Aslan <sup>d</sup>

**⊞ Show more** 

https://doi.org/10.1016/j.neuint.2014.09.005

Get rights and content


## Highlights

- Melatonin treatment decreased COX activity which was increased with 6-OHDA.
- Melatonin treatment decreased PGE2 level which was increased with 6-OHDA.
- Melatonin treatment decreased caspase-3 activity which was increased with 6-OHDA.
- Melatonin treatment decreased neuron death which was increased with 6-OHDA.
- Melatonin treatment increased Bcl-2 amount which was decreased with 6-OHDA.

## **Abstract**

This study aimed to elucidate locomotor activity changes in 6-hydroxydopamine (6-OHDA) induced Parkinson's disease (PD) and investigate the possible beneficial effects of melatonin on altered levels of locomotor activity, cyclooxygenase (COX), prostaglandin E2 (PGE2), nuclear factor

kappa-B (NF-κB), nitrate/nitrite and apoptosis. Male Wistar rats were divided into five groups: vehicle (V), melatonin-treated (M), 6-OHDA-injected (6-OHDA), 6-OHDA-injected + melatonintreated (6-OHDA-Mel) and melatonin treated + 6-OHDA-injected (Mel-6-OHDA). Melatonin was administered intraperitoneally at a dose of 10 mg/kg/day for 30 days in M and Mel-6-OHDA groups, for 7 days in 6-OHDA-Mel group. Experimental PD was created stereotactically via unilateral infusion of 6-OHDA into the medial forebrain bundle (MFB). The 6-OHDA-Mel group started receiving melatonin when experimental PD was created and treatment was continued for 7 days (post-treatment). In the Mel-6-OHDA group, experimental PD was created on the 23rd day of melatonin treatment and continued for the remaining 7 days (pre- and post-treatment). Locomotor activity performance decreased in 6-OHDA group compared with vehicle; however melatonin treatment did not improve this impairment. Nuclear factor kappa Bp65 and Bcl-2 levels were significantly decreased while COX, PGE2 and caspase-3 activity were significantly increased in 6-OHDA group. Melatonin treatment significantly decreased COX, PGE2 and caspase-3 activity, increased Bcl-2 and had no effect on NF-κB levels in experimental PD. 6-Hydroxydopamine injection caused an obvious reduction in TH positive dopaminergic neuron viability as determined by immunohistochemistry. Melatonin supplementation decreased dopaminergic neuron death in 6-OHDA-Mel and Mel-6-OHDA groups compared with 6-OHDA group. Melatonin also protected against 6-OHDA-induced apoptosis, as identified by increment in Bcl-2 levels in dopaminergic neurons. The protective effect of melatonin was more prominent for most parameter following 30 days treatment (pre- and post-) than 7 days post-treatment. In summary, melatonin treatment decreased dopaminergic neuron death in experimental PD model by increasing Bcl-2 protein level and decreasing caspase-3 activity.



## Keywords

Melatonin; 6-Hydroxydopamine; Cyclooxygenase; Prostaglandin E2; Nuclear factor kappa B; Apoptosis

Recommended articles Citing articles (15)

View full text

Copyright © 2014 Elsevier Ltd. All rights reserved.



About ScienceDirect Remote access Shopping cart Advertise Contact and support Terms and conditions Privacy policy

We use cookies to help provide and enhance our service and tailor content and ads. By continuing you agree to the use of cookies.

Copyright © 2019 Elsevier B.V. or its licensors or contributors. ScienceDirect ® is a registered trademark of Elsevier B.V.

